UCLH

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

  NCT07207057· Phase 3· Source

• Active, not recruiting

  Analysis of Screen-detected Lung Cancers' Genomic Traits

  NCT04204499· Source

• Active, not recruiting

  The SUMMIT Study: A Cancer Screening Study

  NCT03934866· Source

• Active, not recruiting

  Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

  NCT02998567· Phase 1· Source

• Active, not recruiting

  Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

  NCT02417662· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting
• Parkinson disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

  NCT05921760· Phase 1/2· Source

• Completed

  The Role of tHyroid cAncer Specific Patient Concerns iNventory (PCI-TC) in Enhancing Shared decisiOn Making

  NCT06322160· Source

• Completed

  Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

  NCT03430700· Phase 2· Source